4-[4-(环氧乙烷-2-基甲氧基)苯基]-1,2,3-噻二唑 | 59834-07-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-[4-(环氧乙烷-2-基甲氧基)苯基]-1,2,3-噻二唑
• 中文别名: 4-[4-(环氧乙烷-2-甲氧基)苯基]-1,2,3-噻二唑
• 英文名称: 3-[4-(1,2,3-thiadiazole-4-yl)phenoxy]-1,2-propenoxide
• 英文别名: 4-[4-(oxiran-2-ylmethoxy)phenyl]-1,2,3-thiadiazole；4-[4(2,3-epoxypropoxy)phenyl] 1,2,3-thiadiazole；4-[4(2,3-epoxypropoxy)phenyl]-1,2,3-thiadiazole；4-[4-(oxiran-2-ylmethoxy)phenyl]thiadiazole
• CAS: 59834-07-0
• 化学式: C₁₁H₁₀N₂O₂S
• mdl: MFCD01571095
• 分子量: 234.279
• InChiKey: LIGGKGOCYSZEDL-UHFFFAOYSA-N

物化性质

• 熔点：
  70 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  75.8
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R20/21/22,R36/37/38
• 安全说明：
  S26,S36/37/39

SDS

Name:	4-[4-(Oxiran-2-ylmethoxy)phenyl]-1 2 3-thiadiazole 95+% Material Safety Data Sheet
Synonym:
CAS:	59834-07-0

Section 1 - Chemical Product MSDS Name:4-[4-(Oxiran-2-ylmethoxy)phenyl]-1 2 3-thiadiazole 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
59834-07-0	4-[4-(Oxiran-2-ylmethoxy)phenyl]-1,2,3	95+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 59834-07-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 70 - 72 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H10N2O2S
Molecular Weight: 234

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 59834-07-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-[4-(Oxiran-2-ylmethoxy)phenyl]-1,2,3-thiadiazole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 59834-07-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 59834-07-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 59834-07-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-[4-(环氧乙烷-2-基甲氧基)苯基]-1,2,3-噻二唑 以 二氯甲烷 、 叔丁胺 、 叔丁醇 为溶剂， 生成 4-[4(3-t-butylamino-2-hydroxypropoxy)phenyl]-1,2,3-thiadiazole
  参考文献：
  名称：

  .beta.-Adrenergic blocking agents in the 1,2,3-thiadiazole series

  摘要：

  新型4-[2,3或4(3-氨基-2-羟基丙氧基)苯基]-和5-[2,3或4(3-氨基-2-羟基丙氧基)苯基]-1,2,3-噻二唑衍生物，可能在噻二唑环的C-5或C-4位置进一步被较低的烷基，苯基，三氟甲基，羧基，烷氧羰基，氰基或氨基羰基取代，以及其药用可接受的酸盐，以及生产这类化合物的方法；4-[4(3-t-丁基氨基-2-羟基丙氧基)苯基]-1,2,3-噻二唑和5-[4(3-t-丁基氨基-2-羟基丙氧基)苯基]-1,2,3-噻二唑是该类的代表。这些化合物具有心血管活性，并可用于治疗哺乳动物的心脏异常病症。

  公开号：

  US03940407A1
• 作为产物：
  描述：

  1-[4-(烯丙氧基)苯基]乙酮 在 氯化亚砜 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 氯仿 为溶剂， 反应 33.0h， 生成 4-[4-(环氧乙烷-2-基甲氧基)苯基]-1,2,3-噻二唑
  参考文献：
  名称：

  一系列1,2,3-噻二唑和1,2,3-硒代二唑衍生物的合成，抗菌和体外抗肿瘤活性。

  摘要：

  制备了取代的1,2,3-硫杂-或1,2,3-硒代二唑（4a-c）的三种衍生物，并通过不同的化学技术对其进行了表征。对这些化合物的抗微生物和抗肿瘤活性进行了评估。化合物4a（环氧丙烷衍生物），4b（甲醛衍生物）和4c（苯衍生物）对酵母样真菌白色念珠菌有活性。化合物4a对革兰氏阴性大肠杆菌有活性，化合物4c对革兰氏阳性金黄色葡萄球菌有活性。对于抗肿瘤活性，化合物4b和4c对所有测试的肿瘤细胞系SW480，HCT116，C32，MV3，HMT3522和MCF-7均具有活性。化合物4c对SW480，HCT116和MCF-7肿瘤细胞系的活性大于化合物4b的活性，并且大于参考抗肿瘤5-氟尿嘧啶的活性。总之，许多制备的1,2,3-硫杂-或1,2,3-硒代二唑化合物显示出有希望的抗真菌，抗菌和体外抗肿瘤活性。需要进一步研究以探索活性化合物诱导其细胞毒性的机制。

  DOI：

  10.2147/dddt.s86054

文献信息

• 1,2,3-Thiadiazoles with Unsaturated Side Chains; Synthesis, Polymerization, and Photocrosslinking
  作者：Mousa Al-Smadi、Herbert Meier、Norbert Hanold、Helga Kalbitz

  DOI：10.1055/s-0029-1216879

  日期：2009.8

  1,2,3-Thiadiazoles with polymerizable functionalities in the 4-position were synthesized as potential negative photoresists. The polymerization to soluble, film-forming materials must leave the heterocyclic rings intact, because they are needed for photocrosslinking reactions to give insoluble materials. 1,2,3-Thiadiazoles 1 cycloeliminate N2 on irradiation. The resulting 1,3-diradicals 2 have various

  合成了在4位具有聚合功能的1,2,3-噻二唑作为潜在的负性光刻胶。聚合成可溶的成膜材料必须使杂环完整无缺，因为光交联反应需要它们才能产生不溶的材料。1,2,3-噻二唑1在照射时可消除N 2。将得到的1,3-双自由基2具有用于稳定进程导致炔烃的各种选项3或更高的杂环5 - 12。必须避免原子硫的产生及其在这些后续反应中的参与。因此，像模型化合物1a这样的系统，其中在此选择了1，3-二价形式2-亚甲基-1，3-二硫代（二硫富烯）9。优化最终产生了两种材料作为光致抗蚀剂。单体1c可以在三氟化硼的存在下聚合成可溶性1c'，其在辐射下形成1c'作为交联的不溶性聚合物。此外，噻二唑1f连接于聚苯乙烯26。所得的可溶性聚合物1i '在辐射下产生不溶性材料1i''。 环二聚-环消除-杂环-光化学-光刻胶
• US3940407A
  申请人：——

  公开号：US3940407A

  公开（公告）日：1976-02-24
• Synthesis, antimicrobial and in vitro antitumor activities of a series of 1,2,3-thiadiazole and 1,2,3-selenadiazole derivatives
  作者：Nizar Mhaidat、Mousa Al-Smadi、Fouad Al-momani、Karem Alzoubj、Iman Mansi、Qosay Al-Balas

  DOI：10.2147/dddt.s86054

  日期：——

  Three derivatives of substituted 1,2,3-thia- or 1,2,3-selenadiazole (4a-c) were prepared and characterized by different chemical techniques. These compounds were evaluated for their antimicrobial and antitumor activities. Compounds 4a (propenoxide derivative), 4b (carbaldehyde derivative), and 4c (benzene derivative) were active against the yeast-like fungi Candida albicans. Compound 4a was active

  制备了取代的1,2,3-硫杂-或1,2,3-硒代二唑（4a-c）的三种衍生物，并通过不同的化学技术对其进行了表征。对这些化合物的抗微生物和抗肿瘤活性进行了评估。化合物4a（环氧丙烷衍生物），4b（甲醛衍生物）和4c（苯衍生物）对酵母样真菌白色念珠菌有活性。化合物4a对革兰氏阴性大肠杆菌有活性，化合物4c对革兰氏阳性金黄色葡萄球菌有活性。对于抗肿瘤活性，化合物4b和4c对所有测试的肿瘤细胞系SW480，HCT116，C32，MV3，HMT3522和MCF-7均具有活性。化合物4c对SW480，HCT116和MCF-7肿瘤细胞系的活性大于化合物4b的活性，并且大于参考抗肿瘤5-氟尿嘧啶的活性。总之，许多制备的1,2,3-硫杂-或1,2,3-硒代二唑化合物显示出有希望的抗真菌，抗菌和体外抗肿瘤活性。需要进一步研究以探索活性化合物诱导其细胞毒性的机制。
• .beta.-Adrenergic blocking agents in the 1,2,3-thiadiazole series
  申请人：Syntex (U.S.A.) Inc.

  公开号：US03940407A1

  公开（公告）日：1976-02-24

  Novel 4-[2,3 or 4(3-amino-2-hydroxypropoxy) phenyl]- and 5-[2,3 or 4(3-amino-2-hydroxypropoxy) phenyl]-1,2,3-thiadiazole derivatives which may be further substituted at the C-5 or C-4 position of the thiadiazole ring, respectively, by a lower alkyl, phenyl, trifluoromethyl, carboxy, alkoxycarbonyl, cyano or an aminocarbonyl group, and the pharmaceutically acceptable acid addition salts thereof and processes for the production of such compounds; 4-[4(3-t-butylamino-2-hydroxypropoxy)phenyl]-1,2,3-thiadiazole and 5-[4(3-t-butylamino-2-hydroxypropoxy)phenyl]-1,2,3-thiadiazole are representative of the class. These compounds possess cardiovascular activity and are useful for the treatment of abnormal heart conditions in mammals.

  新型4-[2,3或4(3-氨基-2-羟基丙氧基)苯基]-和5-[2,3或4(3-氨基-2-羟基丙氧基)苯基]-1,2,3-噻二唑衍生物，可能在噻二唑环的C-5或C-4位置进一步被较低的烷基，苯基，三氟甲基，羧基，烷氧羰基，氰基或氨基羰基取代，以及其药用可接受的酸盐，以及生产这类化合物的方法；4-[4(3-t-丁基氨基-2-羟基丙氧基)苯基]-1,2,3-噻二唑和5-[4(3-t-丁基氨基-2-羟基丙氧基)苯基]-1,2,3-噻二唑是该类的代表。这些化合物具有心血管活性，并可用于治疗哺乳动物的心脏异常病症。